Genetic Technologies Ltd (GENE)
US37185R4065 - ADR
Overall GENE gets a fundamental rating of 1 out of 10. We evaluated GENE against 57 industry peers in the Life Sciences Tools & Services industry. GENE may be in some trouble as it scores bad on both profitability and health. GENE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year GENE has reported negative net income.
GENE had a negative operating cash flow in the past year.
GENE had negative earnings in each of the past 5 years.
In the past 5 years GENE always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -194.25%, GENE is not doing good in the industry: 98.21% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -656.53%, GENE is doing worse than 92.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -194.25% | ||
| ROE | -656.53% | ||
| ROIC | N/A |
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GENE has a Gross Margin (50.94%) which is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for GENE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GENE has been increased compared to 1 year ago.
Compared to 5 years ago, GENE has less shares outstanding
The debt/assets ratio for GENE is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -40.90, we must say that GENE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GENE (-40.90) is worse than 96.43% of its industry peers.
GENE has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
GENE has a Debt to Equity ratio of 0.36. This is comparable to the rest of the industry: GENE outperforms 46.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -40.9 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
GENE has a Current Ratio of 0.88. This is a bad value and indicates that GENE is not financially healthy enough and could expect problems in meeting its short term obligations.
GENE has a worse Current ratio (0.88) than 91.07% of its industry peers.
A Quick Ratio of 0.83 indicates that GENE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.83, GENE is doing worse than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.74% over the past year.
The Revenue for GENE has decreased by -11.76% in the past year. This is quite bad
The Revenue has been growing by 213.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GENE. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for GENE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Genetic Technologies Ltd
NASDAQ:GENE (10/16/2024, 9:36:40 PM)
After market: 0.75 -0.02 (-1.96%)0.765
-0.02 (-1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.68%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.58M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS1.51
BVpS0.36
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -194.25% | ||
| ROE | -656.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.94% | ||
| FCFM | N/A |
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 0.43% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.83 | ||
| Altman-Z | -40.9 |
F-Score4
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.69%
Cap/Sales(5y)201.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A